ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Presentations to highlight clinical utility of ZYNLONTA® as a single agent and in combination Oral presentation to include initial results of investigator-initiated Phase 2 study evaluating...

Related Keywords

San Francisco Bay ,California ,United States ,China ,London ,City Of ,United Kingdom ,San Diego ,Switzerland ,New Jersey ,Chinese ,American ,Loncastuximab Tesirine ,Juan Pablo Alderuccio ,Nicole Riley ,Lausanne Biop ,Mohamed Zaki ,Eugenia Litz ,Mitsubishi Tanabe Pharma Corporation ,Drug Administration ,Exchange Commission ,Duration Loncastuximab Tesirine ,San Diego Convention Center On ,European Medicines Agency ,American Society Of Hematology ,Linkedin ,European Commission ,Company Annual Report On Form ,European Union ,American Society ,Annual Meeting ,Chief Medical Officer ,Limited Duration Loncastuximab Tesirine ,Refractory Follicular Lymphoma ,Manchester Grand Hyatt San Diego ,Grand Hall ,Sustained Circulating Tumor ,Refractory Diffuse Largeb Cell ,Global Study ,Novel Agents ,Adolescent Relapsed ,Refractoryb Cell Non Hodgkin Lymphoma ,Prospective Therapeutic Trials ,Manageable Safety Profile ,Heavily Pretreated Chinese Patients ,Diffuse Largeb Cell Lymphoma ,Hallsg H ,San Diego Convention Center ,San Francisco Bay Area ,Private Securities Litigation Reform Act ,Swedish Orphan Biovitrum ,European Economic Area ,Infrastructure Investment ,Jobs Act ,Healthcare Royalty Management ,Blue Owl ,Annual Report ,Markets ,